Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)

Slides:



Advertisements
Similar presentations
MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Advertisements

ALS Research Yesterday, Today and Tomorrow Heather D. Durham, PhD.
AGEING CAN BE DEFINED AS THE PROGRESSIVE LOSS OF FUNCTION ACCOMPANIED BY DECREASING FERTILITY AND INCREASING MORTALITY.
Crystallization and Dimer Exchange of the Protein Superoxide Dismutase Emily Clark Dr. Joe Beckman Department of Biochemistry/ Biophysics Oregon State.
Amyotrophic lateral sclerosis (Lou Gehrig’s Disease)
Motor neuron disease What are motor neuron diseases? Who is at risk? What are the causes motor neuron diseases? How are they classified? What are the symptoms.
Mechanisms of Bcl-2 in Programmed Cell Death Laura Beth Hill St. Edward’s University.
Mechanisms of Bcl-2 in Programmed Cell Death Laura Beth Hill St. Edward’s University.
Aging changes of the Musculoskeletal System
Comparing the Toxicity of Zinc Deficient Superoxide Dismutase (SOD) and the Quad SOD mutant: Implications for Amyotrophic Lateral Sclerosis Jesse Fitzpatrick.
An Investigation of the Interactions Between Zinc-deficient and Copper, Zinc Superoxide Dismutase Katie Meyers Dr. Joe Beckman Department of Biochemistry/Biophysics.
Motor Neurone Disease Different types & Life Expectancy
Zinc-deficient SOD in ALS Emily Clark Dr. Joe Beckman Department of Biochemistry/Biophysics.
Amyotrophic Lateral Sclerosis (ALS)
ALS Kate Crain. Amyotrophic Lateral Sclerosis Lou Gehrig Disease Charcot’s Syndrome.
Control of movement Four subsystems: Lower motor system- Grey matter of spinal cord and brainstem-contain lower motor neurons and lower circuit neurons-the.
Investigation of mutated Cu/Zn Superoxide Dismutase Sam Schuberg Beckman Laboratory Howard Hughes Medical Institute: Summer 2007.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Part I Mr. Robert Middelton … Over the past few years, he noticed...a slowly developing weakness initially in his hands and arms, now spreading to his.
Amyotrophic Lateral Sclerosis (ALS) Sarah Belair and Hannah McLaughlin.
Cellular Degeneration and Ageing Susan Rutherford and Sarah Christie.
Nervous System Human Body Systems Project Caroline Crinion.
Lou Gehrig's Disease By: Brittany Harden.
Amyotrophic lateral sclerosis (ALS). What is amyotrophic lateral sclerosis? It is a progressive neurological disease that affects the control of muscle.
By Intracerebroventricular Delivery of VEGF in a Rat Model of ALSEGF in a Rat Model of ALS Treatment of Motoneuron Degeneration.
By: Sam Biller + Ryan Coughlin. Neurons are nerve cells that transfer information within the body. The structure of Neurons allows them to use pulses.
PATRICK CASEY FALL 2007 PARAMEDIC CLASS Amyotrophic Lateral Sclerosis.
The Muscular System.
Amyotrophic Lateral Sclerosis and Superoxide Dimutase 1 (SOD1) Iasson Yi CHEM 4700.
Oxidative Stress By: Andrew Lorusso. Overview Alvaro Estevez an associate professor at the University of Central Florida led a multi-university team that.
Health Presentation Amyotrophic Lateral Sclerosis Zhenette Stevens.
LOU GEHRIG’S DISEASE.  Also known as Amyotrophic Lateral Sclerosis  Is a disease of the nerve cells in the brain and spinal cord that control voluntary.
Unit 2 Chapter 4 (pgs 76-80) Patrick’s case study
Amyotrophic Lateral Sclerosis (ALS)
Programmed Cell Death. Why do some cells need to die? To accomplish morphogenetic ends, eg. Separation of fingers during embryogenesis of the hand To.
Molecular Biology and Genetics of Amyotrophic Lateral Sclerosis Michael Sidel February 13, 2008.
漸凍症 amyotrophic lateral sclerosis. Lou Gehrig's disease 1939 Jean-Martin Charcot Amyotrophic lateral sclerosis (ALS) (Rosen DR et al. Nature 1993) 1869.
 Carry impulses from the Central Nervous System to perform muscle movement  Motor Neurons are known as the control muscle  They directly or indirectly.
Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)
Patient #5 ALS. Patient Background and Problems Patient #5- Andrew, a 45 year-old single father of two, comes to you in confidence. He’s noticed that.
Electromyography Tatiana Steinwarz.
The Neurochemistry of Friedreich’s Ataxia By: Michelle Donnelly, Virginia Gamero, Vinson Li, and Pooja Maharajh PHM142 Fall 2015 Coordinator: Dr. Jeffrey.
Douglas Todey. Functions The three main functions of the muscle system are to produce motion, provide stability, and generate heat The three different.
Amyotrophic Lateral Sclerosis (ALS)
ALS Samuel Awad & Osama Jamali. Introduction ALS is one of the most common neuromuscular diseases worldwide, and people of all races and ethnic backgrounds.
Motor Unit & It ’ s Excitation By: Baljit Brar. What Is a Motor Unit? A Motor Unit is described as being a motor neuron plus the muscle fibres that it.
Mitochondrial function in Cell death in PD. Pathology Loss of SN pigmented dopamine neurons Lewy bodies Lewy neurites-multiple brain regions Lewy bodies.
Under the supervision of miklós jászberényi
Role of heat shock proteins in aging
Charcot-Marie- Tooth Disease Jessica Tzeng. History  Named after Jean-Martin Charcot, Pierre Marie (Charcot’s pupil), and Howard Henry Tooth  Not a.
Amyotrophic Lateral Sclerosis
Stephen Hawking. Biography Stephen William Hawking was born on 8 January In Oxford, England. Stephen then went on to Cambridge to do research in.
Motor neuron disease.
N deg - 1 Characteristics of neurons u Cytoskeletal organization u Microtubules and motors u Neuronal intermediate filaments u Neurofilaments u Peripherin,
ALS or Lou Gehrig’s disease By: Nathaniel Baughman.
Amyotrophic Lateral Sclerosis (ALS). Also know as Lou Gehrig's Disease Named after the New York Yankees baseball star who played first base and was diagnosed.
ZOO405 by Rania Baleela is licensed under a Creative Commons Attribution- NonCommercial-ShareAlike 3.0 Unported LicenseRania BaleelaCreative Commons Attribution-
AMYOTROPHIC LATERAL SCLEROSIS Presentation by: Laura Bigelow EXS 486.
Amyotrophic Lateral Sclerosis (ALS)
Muscular Tissue Skeletal Cardiac Smooth
A potential therapy for ALS
Amyotrophic Lateral Sclerosis
What does this protein make up or do? amyotrophic lateral sclerosis
Review What does homeostasis mean? What are the two branches of the nervous system? What are the three types of neurons?
ALS disease pathology and proposed disease mechanisms.
2/15/2019 Shadab Salehpour.
Autophagy in the Pathogenesis of Disease
The Ubiquitin Proteasome System in Neurodegenerative Diseases
By Ivy Stites and Keya Patel
Presentation transcript:

Amyotrophic Lateral Sclerosis (ALS; Lou Gehrig’s disease)

Lou Gehrig

ALS is a “motor-neuron” disease, a neurodegenerative disease characterized by the selective death/degeneration of upper motor neurons (in the brain) and lower motor neurons (in the spinal cord). The upper motor neurons normally send the signals to the lower motor neurons, which send signals to muscles.

www.alsa.org

www.alsa.org

A-myo-trophic Lateral Sclerosis Amyotrophic: no muscle nourishment Lateral: refers to the the areas in a person's spinal cord where portions of the nerve cells that signal and control the muscles are located Sclerosis: scarring of the affected nerves

Severe atrophy of anterior spinal roots in motorneuron disease Degeneration of motor neurons in the spinal cord and brainstem results in degeneration of pyramidal tracts and severe atrophy of anterior spinal roots which is demonstrated here.

Atrophic muscle fibers in ALS patients

Muscular atrophy in ALS

Symptoms Earliest signs: 1-twitching (fasciculation), stiffness, cramping 2-weakness of the arms and of the legs. This results in an increased frequency of stumbling on uneven pavement or difficulty in climbing stairs. Arm weakness may lead to difficulty in grasping or holding a cup, for instance, or loss of coordination in fingers 3-more rarely, weakness of the muscles of the mouth. This results in difficulties for the patient to chew, swallow and speak. Later signs: The progression of the disease is accompanied by weight loss, fatigue, exaggerated reflexes, and decreased coordination. Ultimately, patients cannot walk, stand, eat, or breathe without assistance. Increased susceptibility to pneumonia and respiratory failure causes half to die within three years. However, muscles that controls eye movements and urinary sphincters are spared.

Diagnosis of ALS -No biological marker has been identified yet. -Series of clinical and neurological exams -MRI -myelogram of cervical spine (an x-ray analysis that allows the detection of lesions in selected area of the spinal cord) muscle and/or nerve biopsy electromyography (EMG) and nerve conduction velocity (NCV), to measure muscle response to nervous stimulation.

MRI in Amytrophic Lateral Sclerosis (ALS)

Electromyography (EMG) A needle electrode is inserted through the skin into the muscle. Each muscle fiber that contracts will produce an action potential. The presence, size, and shape of the wave form of the action potential produced on the oscilloscope, provides information about the ability of the muscle to respond to nervous stimulation.

Epidemiology of ALS Incidence: 1-2 in 100,000 each year. At the moment in the U.S. there are 25,000 people affected by the disease. Median age of onset is 55 years old. Gender-related incidence: female:male ratio is 4:5. 10% of the cases are inherited, familial cases (FALS), whereas the 90% of the cases are sporadic (SALS) The life-span of a patient affected by ALS is 3 to 5 years, after the diagnosis.

Genetic of ALS

Toxic mechanisms in ALS

Is ALS a mitochondrial disease?

Evidences of mitochondrial dysfunction in SALS: -mitochondria aggregate in skeletal muscle and intramuscular nerve -mitochondria show abnormalities in proximal axons and nerves of the anterior horn of spinal cord -increased mitochondrial volume and calcium level -dysfunction of mitochondrial complex I and IV Decreased ATP production

Calcium deposits in mitochondria of ALS patients CONTROL ALS Calcium deposits in mitochondria of ALS patients Syklos et al.,

Evidences that SOD1 could be involved in SALS -Symptoms and pathology of SALS patients are the same as in SOD1 related FALS patients -Pathologic alterations of SOD1 mutant mice are similar to those observed in SALS patients Formation of mitochondrial vacuoles Expansion and rupture of the mitochondrial outer membrane Alterations of calcium homeostasis in the mitochondria Alterations of mitochondrial membrane potential Formation of calcium deposits within the mitochondria

Superoxide Dismutase 1 SOD1 SOD1 is a ubiquitous mostly cytosolic protein SOD1 is comprised of 153 aa with an approximate molecular weight of 16kDa and is an active homodimer Each of the two dimers of SOD1 binds a Cu++ and a Zn++ ion. The reduction of Cu++ to Cu+ is behind the mechanism of SOD1 in regulating the dismutation of superoxide ion O2-. into hydrogen peroxide H2O2 Cu2+ + O2-· Cu+ + O2 Cu+ + O2-· + 2H+ Cu2+ + H2O2 2 O2-· + 2H+ H2O2 + O2 A catalase will subsequently reduce hydrogen peroxide to water.

SOD1 structure: the functional homodimer

Most common mutations in SOD1 related FALS

SOD1 misfolds and aggregates in FALS SOD1A4V motorneurons SEDI Ab SEDI-reactive SOD1 SOD1

Possible roles of mutated SOD1 in FALS Loss of physiological function: impaired dismutase activity Gain of toxic function: 1) Aberrant redox chemistry, probably due to changes in the conformation of SOD1, that leave the channel (the portion of the molecule accepting superoxide ion, i.e.) able to accept larger molecules. This can lead to peroxidation, tyrosine nitrosylation and reverse catalysis (due to improper binding of Zn++ to the molecule that leads to formation of superoxide ion rather than dismutase activity). These activities are not a characteristic of ALL SOD1 mutations, thus remain partially controversial. 2) Protein instability and SOD1 aggregation. These activities are characteristic of all SOD1 mutants.

Models of mutant SOD1-mediated toxicity

Mutant SOD1 may mediate cytotoxic reactions involving: 1) Copper catalysis/Zn-mediated toxicity 2) Protein aggregation Mutant SOD1 may mediate cytotoxic reactions involving: 1) Copper catalysis/Zn-mediated toxicity 2) Protein aggregation 4 4 1 1 O-O…Cu Zn WT O-O…Cu Zn WT H H O O Cu Cu Zn Zn H H O O 2 2 3 3 Aggregation Aggregation .OH .OH Peroxidation Peroxidation Cu Cu ONOO ONOO Zn Zn toxic toxic Cu Cu Zn Zn toxic toxic NO-Tyr NO-Tyr Cu, Zn Toxicity Cu, Zn Toxicity Tyrosine Nitration Tyrosine Nitration P.Pasinelli

SOD1 and FALS -More than 125 mutations have been found on the SOD1 gene, 114 are related to ALS, most of them are missense mutations, only 12 are nonsense mutations or deletion mutants. -Most mutations reduce dismutation activity, however others retain full dismutase activity, still are related to the disease. Moreover, there is NO CLEAR CORRELATION between enzyme activity and progression of the disease. -In addition, in animal models, gene KO for SOD1 does not cause motorneuron disease, whereas overexpression of SOD1 does. In this respect, the simple manipulation of SOD1 dismutase activity IS NOT necessarily behind ALS/motorneuron disease.

1-SOD1 could be modified in SALS 2-SALS and FALS may share the same toxic mechanism of toxicity of SOD1

Can SOD1 form aggregates also in SALS?

wtSOD1 can be oxidized

SOD1 conformation-specific antibody

Conformation-specific SOD1 antibody detects oxSOD1 in non-denaturing conditions…

…but not in denaturing conditions: SOD1 oxidation as a mechanism to form SOD1 aggregates

SOD1 oxidation inhibits anterograde Fast Axonal Transport FAT

oxSOD1 affects the activity of p38MAPK, a protein that regulates FAT

Inhibition of p38MAPK reverts the effects of oxSOD1 on FAT

Sequestration of conformation-specific oxSOD1 reverts the effects of wtSOD1 on FAT in SALS

Conformation-specific SOD1 antibody reacts with wtSOD1 only in SALS

How SOD1 aggregates could be toxic? 1- Formation of small and large aggregates that may impairs proteasomal activity. This would result in lack of proper degradation of different proteins including toxic mutant SOD1. 2- Sequestration within the aggregate of proteins that are important for the cell, like heat shock proteins (HSP70), thus impairing the physiological “protective” activity of these proteins. 3-SOD1 can sequester into aggregates the anti-apoptotic Bcl2. 4- Formation of SOD1 aggregates can be related to mitochondrial dysfunction and apoptosis.

SOD1 aggregates: mitochondrial dysfunction and apoptosis

1- Cluster of abnormal mitochondria and morphological defect (in muscles cells and in motorneuron) Complex I and IV are defective, paralleled by increased mitochondrial Ca++ levels. 2-in vitro and in vivo, SOD1 mutants *cause depolarization of mitochondria *decrease levels of ATP 3- Vacuolated mitochondria: detachment between the outer and the inner membrane, crystae disruption. Is mitochondrial dysfunction a cause or a consequence?

How could mutant SOD1 be related to mitochondrial defects? Altering mitochondrial structure, causing formation of vacuoles and ultimately rupture of the mitochondrial outer membrane leading to apoptosis

SOD1 associates to Bcl2, but not to Bax, in vitro… Exogenous SOD1 Endogenous SOD1

…and in vivo mice Human spinal cord

Bcl2 binds aggregated SOD1 in animal models of ALS…

…and in spinal cord of ALS patients FALS SOD1 A4V

Mutant SOD1 binds Bcl2 specifically in the mitochondria

SOD1 aggregates recruit Bcl2 and start apoptosis in FALS

More importantly: Mutant SOD1 is very toxic when in the mitochondria INSIDE THE MITOCHONDRIA *forming aggregates *interfering with cytochrome c in the peroxisomes (fusion of the peroxisomes membranes, formation of pores and release of cytochrome c, initiation of apoptosis) OUTSIDE THE MITOCHONDRIA *forming aggregates in the outer membrane, this leads to disruption of TOM (Translocator Outer Membrane complex) disruption of protein transport in the mitochondrion. *forming aggregates with anti-apoptotic Bcl2 at the surface of the mitochondria, thus leading to apoptosis

The mitochondrion as a target of mutant SOD1

Defective axonal transport in ALS

Characteristic of ALS is axonal swelling www.afip.org

Axonal transport: Intracellular transport in neurons -Neurons are polarized cells. The presence of a positive or negative pole provides driving force to regulate anterograde or retrograde transport. -Anterograde: from cell body to neuronal end. Positive pole. -Retrograde: from neuronal end back to cell body. Negative pole. What is transported? Proteins (synthesized in the cell body) Organelles-Mitochondria Vesicles

Axonal Transport

Proteins regulating axonal tranport Kinesin 1 Anterograde transport Dynein/dynactin Retrograde transport

Point mutations in the gene of dynactin are associated to FALS

ALS and axonal transport In motorneurons, axons are very long thus both anterograde and retrograde transport are complex events Neuronal transport is reduced in ALS Deposition of neurofilament Defects and mutations in dynein

Deposition of fibrillar proteinacious material in Amyotrophic Lateral Sclerosis (ALS) Ross and Poirier, 2004

Axonal transport in ALS -Increased anterograde and decreased retrograde axonal transport in ALS patients. -Dynactin mutations associated to impaired retrograde transport -Decreased transport of mitochondria also in certain SOD1 mutants

Mechanisms of axonal transport defects: damage to mitochondria

Axonal vacuolation is an early event that precedes neurodegeneration in a model of ALS

Aggregates of G93ASOD1 are found in the axons, co-localizing with dynein: possible role of mutant SOD1 in damaging axonal transport Neuroreport

Only G93ASOD1, not WT SOD1, forms aggregates in the axon that co-localize with dynein

Model of aberrant interaction between SOD1 aggregates and dynein on FALS

What about autophagy in ALS?

Autophagy increases in SOD1G93A mutant mice Activation of the autophagy marker LC3 follows the disease progression

Mitochondrial dysfunction and number of autophagic vacuoles follows the progression of the disease in SOD1G93A mutant mice

The expression of the autophagy marker LC3 does not change in ALS animal model

What about HSP that can regulate autophagy in ALS?

HspB8 is more abundant in the spinal cord of ALS mice

Mutant SOD1 co-localizes with HspB8 in ALS mice

HspB8 increases autophagic markers in ALS mice

SOD1 mutation in ALS: gain of toxic function rather than loss of physiologic function

SOD1siRNA improves ALS symptoms and viability in a SOD1G93A mutant mouse.